A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY-1)
FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors
Sponsor: Day One Biopharmaceuticals, Inc.
A PHASE2 clinical study on Advanced Solid Tumor and Low-grade Glioma, this trial is actively recruiting participants. The trial is conducted by Day One Biopharmaceuticals, Inc. and has accumulated 14 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
May 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 9 earlier versions
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Feb 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Jul 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jun 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Day One Biopharmaceuticals, Inc.
- Pacific Pediatric Neuro-Oncology Consortium
For direct contact, visit the study record on ClinicalTrials.gov .